Trial Profile
A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Bevacizumab
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms Study 22
- Sponsors AstraZeneca; MedImmune
- 30 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Mar 2025.
- 10 Jun 2023 Results of Population Pharmacokinetics and Exposure-Response Analysis published in the Journal of Clinical Pharmacology
- 07 Dec 2022 Pooled analysis from NCT02519348, NCT03298451 assessing the pharmacokinetics, exposure-response, and exposure-pharmacodynamics relationships of tremelimumab in patients with unresectable hepatocellular carcinoma published in the Clinical Cancer Research